Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial

202175 citationsJournal Articlegold Open Access

Authors

Korea Research Institute of Bioscience and Biotechnology [2020M3A9H5108928] and Chong Kun Dang (CKD) Pharm (Seoul, Korea).

Good health and well-being

Published in: EClinicalMedicine

Volume 41, pp. 101169-101169

Field-Weighted Citation Impact: 4.23